MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
11.67
+0.63
+5.71%
Opening 14:06 04/01 EDT
OPEN
11.08
PREV CLOSE
11.04
HIGH
11.94
LOW
11.08
VOLUME
364.15K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
9.12
MARKET CAP
230.10M
P/E (TTM)
5.08
1D
5D
1M
3M
1Y
5Y
1D
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
NASDAQ · 1d ago
Weekly Report: what happened at KROS last week (0323-0327)?
Weekly Report · 2d ago
Weekly Report: what happened at KROS last week (0316-0320)?
Weekly Report · 03/23 10:07
Weekly Report: what happened at KROS last week (0309-0313)?
Weekly Report · 03/16 10:07
Keros Therapeutics Inc Files Initial Beneficial Ownership Statement for Director Charles W. Newton
Reuters · 03/11 20:38
Keros Therapeutics Director Jean Jacques Bienaime Acquires Common Shares
Reuters · 03/11 20:37
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
TipRanks · 03/10 20:35
Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL)
TipRanks · 03/10 10:41
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.